- Home
- STTK vs NEXM Comparison
STTK vs NEXM Comparison
Compare STTK & NEXM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- NEXM
- Stock Information
- Founded
- STTK 2016
- NEXM N/A
- Country
- STTK United States
- NEXM Canada
- Employees
- STTK N/A
- NEXM N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- NEXM
- Sector
- STTK Health Care
- NEXM
- Exchange
- STTK Nasdaq
- NEXM Nasdaq
- Market Cap
- STTK 112.6M
- NEXM 130.4M
- IPO Year
- STTK 2020
- NEXM N/A
- Fundamental
- Price
- STTK $1.98
- NEXM $5.72
- Analyst Decision
- STTK Hold
- NEXM
- Analyst Count
- STTK 5
- NEXM 0
- Target Price
- STTK $3.00
- NEXM N/A
- AVG Volume (30 Days)
- STTK 411.4K
- NEXM 148.6K
- Earning Date
- STTK 11-13-2025
- NEXM 11-20-2025
- Dividend Yield
- STTK N/A
- NEXM N/A
- EPS Growth
- STTK N/A
- NEXM N/A
- EPS
- STTK N/A
- NEXM N/A
- Revenue
- STTK $2,997,000.00
- NEXM N/A
- Revenue This Year
- STTK N/A
- NEXM N/A
- Revenue Next Year
- STTK N/A
- NEXM N/A
- P/E Ratio
- STTK N/A
- NEXM N/A
- Revenue Growth
- STTK N/A
- NEXM N/A
- 52 Week Low
- STTK $0.69
- NEXM $4.82
- 52 Week High
- STTK $2.71
- NEXM $10.35
- Technical
- Relative Strength Index (RSI)
- STTK 48.57
- NEXM 50.01
- Support Level
- STTK $1.72
- NEXM $5.37
- Resistance Level
- STTK $2.71
- NEXM $6.65
- Average True Range (ATR)
- STTK 0.22
- NEXM 0.39
- MACD
- STTK -0.09
- NEXM -0.01
- Stochastic Oscillator
- STTK 25.05
- NEXM 26.87
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About NEXM NexMetals Mining Corp.
NexMetals Mining Corp is a mineral exploration and development company focused on discovering and advancing high-quality copper-nickel-cobalt-platinum element metals (Cu- Cu-Ni-Co-PGE) resources. The group prioritizes projects in stable, mining-friendly jurisdictions with supportive foreign investment and rule-of-law standards. Its projects are Botswana and Canada.